Free Trial
NASDAQ:BBIO

BridgeBio Pharma Q1 2025 Earnings Report

BridgeBio Pharma logo
$35.29 +1.11 (+3.25%)
Closing price 04/23/2025 03:58 PM Eastern
Extended Trading
$35.22 -0.07 (-0.20%)
As of 04/23/2025 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BridgeBio Pharma EPS Results

Actual EPS
N/A
Consensus EPS
-$0.90
Beat/Miss
N/A
One Year Ago EPS
N/A

BridgeBio Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$57.14 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

BridgeBio Pharma Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Tuesday, April 29, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

BridgeBio Pharma Earnings Headlines

BridgeBio Pharma Inc.
Trump purposefully forcing markets to crash…
Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you ready for it?
BridgeBio: Early Signs Point To Blockbuster Revenues
HC Wainwright Issues Pessimistic Estimate for BBIO Earnings
See More BridgeBio Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BridgeBio Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BridgeBio Pharma and other key companies, straight to your email.

About BridgeBio Pharma

BridgeBio Pharma (NASDAQ:BBIO), a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

View BridgeBio Pharma Profile

More Earnings Resources from MarketBeat